← Back to Screener
Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)
Price$0.59
Favorite Metrics
Price vs S&P 500 (26W)-64.66%
Price vs S&P 500 (4W)-19.39%
Market Capitalization$21.71M
All Metrics
Book Value / Share (Quarterly)$0.04
P/TBV (Annual)1.03x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.34
Price vs S&P 500 (YTD)-48.78%
EPS (TTM)$-0.84
10-Day Avg Trading Volume0.47M
EPS Excl Extra (TTM)$-0.84
EPS (Annual)$-0.60
ROI (Annual)-255.74%
Cash / Share (Quarterly)$0.07
ROA (Last FY)-136.96%
EBITD / Share (TTM)$-0.79
Cash Flow / Share (Annual)$-0.39
P/B Ratio16.99x
P/B Ratio (Quarterly)19.06x
Net Income / Employee (Annual)$-0
Net Interest Coverage (TTM)-3.82x
ROA (TTM)-278.73%
EPS Incl Extra (Annual)$-0.60
Current Ratio (Annual)2.02x
Quick Ratio (Quarterly)0.90x
3-Month Avg Trading Volume0.50M
52-Week Price Return-18.62%
Tangible BV / Share (Quarterly)$0.67
52-Week High$1.65
EPS Excl Extra (Annual)$-0.60
CapEx CAGR (5Y)40.46%
26-Week Price Return-55.91%
Quick Ratio (Annual)1.82x
13-Week Price Return-44.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.15x
Enterprise Value$19.585
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.21
3-Month Return Std Dev91.01%
Net Income / Employee (TTM)$-0
ROE (Last FY)-255.74%
EPS Basic Excl Extra (Annual)$-0.60
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.84
ROI (TTM)-623.25%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.13
Forward P/E4.53x
Price vs S&P 500 (52W)-53.72%
Year-to-Date Return-44.64%
5-Day Price Return-1.93%
EPS Normalized (Annual)$-0.60
ROA (5Y Avg)-223.64%
Month-to-Date Return11.55%
EBITD / Share (Annual)$-0.58
LT Debt / Equity (Annual)0.03x
LT Debt / Equity (Quarterly)0.09x
EPS Basic Excl Extra (TTM)$-0.84
P/TBV (Quarterly)1.74x
P/B Ratio (Annual)5.28x
Book Value / Share (Annual)$0.18
Price vs S&P 500 (13W)-47.08%
Beta2.31x
ROE (TTM)-623.25%
52-Week Low$0.34
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
About
Inspira Technologies Oxy BHN Ltd develops proprietary respiratory support devices designed as a non-invasive alternative to mechanical ventilation for patients with respiratory failure. The company targets a substantial global market with technology addressing the limitations of current invasive treatment standards.